₨ Price status
Not in DRAP list
100s, 10x10s
No official DRAP price published for this brand · Market price: not yet recorded
DRAP registration
Medicine details
AMPILITE contains Ampicillin and is registered with DRAP under number 040214, marketed by ELITE PHARMA. Its price is not in DRAP's published price list.
| Brand | AMPILITE |
|---|---|
| Medicine (generic) | Ampicillin |
| Composition (DRAP registry) | Ampicillin (as Trihydrate) ...... 250mg mg |
| Strength | 250 mg |
| Dosage form | Capsule |
| Pack sizes | 100s, 10x10s |
| Company | ELITE PHARMA |
| DRAP registration no. | 040214 |
| Registered since | 2005-06-18 |
Price comparison
Same medicine with official DRAP prices
Same generic · same dosage form first · lowest pack price first
| Brand | Company | Form and pack | Official DRAP price |
|---|---|---|---|
| Ampicilline 250 mg | Mediate Pharmaceutical Pvt Ltd | Capsule, 12's | PKR 48.02 |
| Ampcin 250 mg | CSH Pharmaceuticals (Pvt.) Ltd., | Capsule, 2x10’s | PKR 84.43 |
| Ampicilline 500 mg | Mediate Pharmaceutical Pvt Ltd | Capsule, 12's | PKR 100.04 |
| Ampcin 500 mg | CSH Pharmaceuticals (Pvt.) Ltd., | Capsule, 2x10’s | PKR 168.86 |
| Ampistal 250 mg | STALLION PHARMACEUTICALS PVT LTD | Capsule, 100’S | PKR 327.90 |
| Empicil 250 Caps 250 mg | UNEXOLABS (PVT) LTD. | Capsule, 100's | PKR 385.95 |
| Empicil 250 Caps 250 mg | UNEXOLABS (PVT) LTD. | Capsule, 10x10 | PKR 385.95 |
| Ampcin 250 mg | CSH Pharmaceuticals (Pvt.) Ltd., | Capsule, 10x10’s | PKR 422.13 |
| Ampicilline 250 mg | Mediate Pharmaceutical Pvt Ltd | Capsule, 10x10's | PKR 428.13 |
| Ampistal 500 mg | STALLION PHARMACEUTICALS PVT LTD | Capsule, 100’S | PKR 604.03 |
Sources: DRAP registered-product records and published lists. Always follow your doctor's or pharmacist's advice before switching brands.
Market price
Price seen in the market
Printed MRP · latest per pack · reviewed by MedInfoBase
No market price recorded yet. Prices of deregulated medicines are set by companies and can change; help by reporting the price printed on the pack.
